APOPTOTIC CELL-DEATH INDUCED BY A MOUSE-HUMAN ANTI-APO-1 CHIMERIC ANTIBODY LEADS TO TUMOR-REGRESSION

被引:26
作者
CONEY, LR
DANIEL, PT
SANBORN, D
DHEIN, J
DEBATIN, KM
KRAMMER, PH
ZURAWSKI, VR
机构
[1] CENTOCOR INC,MALVERN,PA 19355
[2] GERMAN CANC RES CTR,DIV IMMUNOGENET,TUMOR IMMUNOL PROGRAM,W-6900 HEIDELBERG,GERMANY
关键词
D O I
10.1002/ijc.2910580419
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The murine anti-APO-1 antibody(gamma 3, kappa) induces programmed cell death (apoptosis) following binding to the APO-1 antigen (m.w., 48 kDa) expressed, e.g., on activated or malignant lymphocytes. APO-1 expression on malignant cell lines and tissues suggested potential clinical utility supported by anti-APO-1-mediated tumor regression in a nude mouse model. A mouse-human anti-APO-1 chimeric antibody (gamma 3, kappa) with an affinity similar to that of the murine antibody was produced. Chimeric anti-APO-1 showed the same potential to inhibit growth of the SKW6.4 B-lymphoblastoid cell line as murine anti-APO-1. In addition, both the chimeric and murine anti-APO-1 antibodies were equally capable of mediating complete macroscopic tumor regression of a SKW6.4 xenotransplant in SCID mice by induction of apoptosis. Induction of apoptosis was the only mechanism for tumor regression because neither murine nor chimeric anti-APO-1 showed anti-tumor activity against solid H53 tumor (APO-1 antigen-positive, anti-APO-1-resistant) xenotransplants. Our results indicate that the chimeric anti-APO-1 antibody effectively induces apoptosis and suggest that chimeric anti-APO-1 should be evaluated for the treatment of malignant cells expressing the APO-1 antigen. However, chimeric anti-APO-1 might only be used therapeutically when the antibody can be targeted specifically to tumor cells. (C) 1994 Wiley-Liss, Inc.
引用
收藏
页码:562 / 567
页数:6
相关论文
共 21 条
  • [1] ABDELMOULA M, 1989, J IMMUNOL, V143, P526
  • [2] BENARD J, 1985, CANCER RES, V45, P4970
  • [3] COMPARISON OF THE EFFECTOR FUNCTIONS OF HUMAN-IMMUNOGLOBULINS USING A MATCHED SET OF CHIMERIC ANTIBODIES
    BRUGGEMANN, M
    WILLIAMS, GT
    BINDON, CI
    CLARK, MR
    WALKER, MR
    JEFFERIS, R
    WALDMANN, H
    NEUBERGER, MS
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1987, 166 (05) : 1351 - 1361
  • [4] MONOCLONAL-ANTIBODY-MEDIATED APOPTOSIS IN ADULT T-CELL LEUKEMIA
    DEBATIN, KM
    GOLDMANN, CK
    BAMFORD, R
    WALDMANN, TA
    KRAMMER, PH
    [J]. LANCET, 1990, 335 (8688) : 497 - 500
  • [5] DHEIN J, 1992, J IMMUNOL, V149, P3166
  • [6] GREENSPAN NS, 1988, J IMMUNOL, V141, P4276
  • [7] GREENSPAN NS, 1987, J IMMUNOL, V138, P285
  • [8] Hasemann CA, 1989, FUNDAMENTAL IMMUNOLO, P209
  • [9] BIOLOGICAL HALF-LIFE OF NORMAL AND TRUNCATED HUMAN IGG3 IN SCID MICE
    HASSAN, MS
    ABEDIVALUGERDI, M
    LEFRANC, G
    HAMMARSTROM, L
    SMITH, CIE
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1991, 21 (05) : 1319 - 1322
  • [10] THE POLYPEPTIDE ENCODED BY THE CDNA FOR HUMAN CELL-SURFACE ANTIGEN FAS CAN MEDIATE APOPTOSIS
    ITOH, N
    YONEHARA, S
    ISHII, A
    YONEHARA, M
    MIZUSHIMA, S
    SAMESHIMA, M
    HASE, A
    SETO, Y
    NAGATA, S
    [J]. CELL, 1991, 66 (02) : 233 - 243